Interaction between HIV-1 and antibodies modeled with new mathematical precision

May 4, 2017, Public Library of Science
In this work, the authors experimentally determined or collected from the literature parameters that quantitatively define the interaction between Human Immundeficiency Virus 1 (HIV-1) virions and neutralizing antibodies (nAbs) and between HIV-1 virions and the human host during viral transmission. These parameters were subsequently utilized to mathematically model HIV-1 transmission and antibody neutralization, yielding predictions of person-to-person HIV-1 transmission probabilities and the potential protective effects of neutralizing antibodies. Credit: Oliver Brandenberg

An experimental and mathematical analysis has revealed new insights into the interactions between HIV-1 and antibodies that can inhibit transmission of the virus from one person to another. These findings, presented in PLOS Pathogens, could potentially aid development of new treatments and vaccines for HIV-1.

Oliver Brandenberg and Carsten Magnus, working in the group of Alexandra Trkola at the University of Zürich, Switzerland, carried out the new analyses based on a wealth of evidence that certain antibodies—immune system proteins that can target harmful invaders—have a protective effect against HIV-1. Despite this evidence, the quantitative details of the interaction between antibodies and HIV-1 have been unclear.

To better understand this interaction, Trkola's team first performed laboratory experiments on HIV-1 and the antibodies in question, known as neutralizing antibodies (nAbs). Previous studies had shown that nAbs bind to proteins embedded in the virus's outer envelope, preventing these proteins from carrying out their usual role of helping HIV-1 invade host cells.

Up to three antibody molecules can bind to each , but the new experiments showed that just one antibody is sufficient to block an envelope 's function. This result, combined with the number of envelope proteins per virus and the number needed to enter a cell, enabled the scientists to mathematically model the amount of nAbs needed to neutralize HIV-1 in the lab, as well as in animals.

Using their new model, the researchers analyzed the results of previous studies performed on macaques to estimate the probability that a single HIV-1 virus could trigger an infection in a new host. The team was also able to model nAb-HIV-1 interactions during male-to-female transmission in humans and predict the chances of transmission during a single sexual act, as well as the nAb concentration required to prevent infection.

These findings could aid research into nAb-based vaccines and treatments, which have proven complex to develop. Millions of people worldwide are infected with HIV-1, which causes AIDS. While antiretroviral therapy allows many infected people to lead long lives, treatment or prevention with a vaccine is an appealing potential alternative.

"Our study highlights the potential of linking theoretical and experimental approaches in deciphering molecular details of the protective effects of neutralizing against HIV-1 transmission and the transmission process itself," the authors explain. "Building on our modeling approach, post-hoc and pre-treatment modeling analyses of antibody efficacy in passive immunization studies should be attempted to maximize treatment efficacy. "

Explore further: Researchers map pathways to protective antibodies for an HIV vaccine

More information: Brandenberg OF, Magnus C, Rusert P, Günthard HF, Regoes RR, Trkola A (2017) Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. PLoS Pathog 13(5): e1006313. DOI: 10.1371/journal.ppat.1006313

Related Stories

Researchers map pathways to protective antibodies for an HIV vaccine

March 15, 2017
A Duke Health-led research team has described both the pathway of HIV protective antibody development and a synthetic HIV outer envelope mimic that has the potential to induce the antibodies with vaccination.

Towards an HIV vaccine

July 9, 2015
Neutralizing antibodies (Nabs) are immune proteins that recognize, bind to, and trigger the elimination of virus before it can establish a chronic infection. How to elicit a potent Nab response capable of protecting against ...

Scientists identify potent antibody that neutralizes nearly all HIV strains

November 15, 2016
Scientists from the National Institutes of Health have identified an antibody from an HIV-infected person that potently neutralized 98 percent of HIV isolates tested, including 16 of 20 strains resistant to other antibodies ...

Only a limited HIV subset moves from mother to child, study shows

February 15, 2017
In the transmission of HIV-1 from mother to child only a subset of a mother's viruses infects their infants either in utero or via breastfeeding, and the viruses that are transmitted depend on whether transmission occurs ...

HIV vaccine research requires unprecedented path

July 12, 2016
The development of an effective vaccine to prevent HIV infections would represent a critical step toward ending the HIV/AIDS pandemic. Thus far, the only large clinical trial for an HIV vaccine to show promise was the RV144 ...

Antibody combination puts HIV on the ropes

January 25, 2017
Without antiretroviral drug treatment, the majority of people infected with HIV ultimately develop AIDS, as the virus changes and evolves beyond the body's ability to control it. But a small group of infected individuals—called ...

Recommended for you

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.